Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease (MOUNTAIN)

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Diagnostic test, Other, Genetic
Study Type: Observational
SUMMARY

A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria

• 18 years of age or older

Locations
United States
California
University of California San Francisco
RECRUITING
San Francisco
Colorado
University of Colorado Denver
RECRUITING
Aurora
Kansas
University of Kansas
RECRUITING
Kansas City
Michigan
University of Michigan
RECRUITING
Ann Arbor
Contact Information
Primary
Haylie Lengel
haylie.lengel@cuanschutz.edu
970-376-8303
Backup
Joyce S Lee
joyce.lee@cuanschutz.edu
303-724-6109
Time Frame
Start Date: 2024-01-22
Estimated Completion Date: 2034-01
Participants
Target number of participants: 450
Treatments
Patients with RA-ILD
Assessments include:~* Clinical: height, weight, oxygen saturation at rest, and 6-minute walk test.~* Rheumatological: study Rheumatologist will document rheumatoid arthritis symptoms and clinical findings at baseline and follow-up.~* Pulmonary Function Testing: data will be collected from clinically performed spirometry and diffusing capacity for carbon monoxide.~* High-resolution computed tomography (HRCT) imaging: HRCT scans will be collected at baseline and 12 months in line with standard of care for treatment of RA-ILD.~* Lab specimens: peripheral blood will be obtained for DNA, RNA, serum, and plasma at baseline and at 12 months for all sites or every 3-4 months in Colorado. Buccal swabs (cheek) will also be collected once each year.~* Information collected: will include demographics, co-morbidities, disease history, medication history, pulmonary function, radiographic imaging, and transplant/survival status through questionnaires and medical chart review.
Sponsors
Collaborators: University of Michigan, University of Kansas, National Heart, Lung, and Blood Institute (NHLBI), University of California, San Francisco
Leads: University of Colorado, Denver

This content was sourced from clinicaltrials.gov